Drug results: 18
| etofylline clofibrate | whole issue; structure given in first source |
|
| clofibric acid | An antilipemic agent that is the biologically active metabolite of CLOFIBRATE. |
|
| clofibrate | A fibric acid derivative used in the treatment of HYPERLIPOPROTEINEMIA TYPE III and severe HYPERTRIGLYCERIDEMIA. (From Martindale, The Extra Pharmacopoeia, 30th ed, p986) |
|
| aluminium clofibrate | ||
| simfibrate |
|
|
| etofibrate | analog of clofibrate with nicotinic acid substituted on the 2-carbon of the ethyl ester group; structure; RN given refers to parent cpd |
|
| pirifibrate |
|
|
| binifibrate | two nicotinic & one clofibiric radical esterified by glycerol moiety |
|
| nicofibrate |
|
|
| ronifibrate |
|
|
| bezafibrate | An antilipemic agent that lowers CHOLESTEROL and TRIGLYCERIDES. It decreases LOW DENSITY LIPOPROTEINS and increases HIGH DENSITY LIPOPROTEINS. |
|
| fenofibrate | An antilipemic agent which reduces both CHOLESTEROL and TRIGLYCERIDES in the blood. |
|
| choline fenofibrate | metabolite of lipantyl; structure; salt of cholesterylamine & 2-(4-(p-chlorobenzoyl)phenoxy)2-methylpropionic acid |
|
| plafibride | morpholino-methylurea analog of clofibric acid |
|
| clinofibrate |
|
|
| tocofibrate |
|
|
| pemafibrate | Pemafibrate is a selective PPAR-alpha modulator (SPPARM-alpha) that has antihyperlipidaemic activity. |
|
| ciprofibrate | Ciprofibrate is a new derivative of phenoxyisobutyric acid which has a marked hypolipidaemic action. It reduces both LDL and VLDL and hence the levels of triglyceride and cholesterol associated with these lipoprotein fractions. It also increases levels of HDL cholesterol. |
|








Citing DrugCentral © 2025.
License